EpiCept to Raise $2 Million in Registered Direct Offering
February 08, 2012 23:31 ET
|
Immune Pharmaceuticals Inc
EpiCept to Raise $2 Million in Registered Direct Offering
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and...
EpiCept to Present at the 14th Annual BIO CEO & Investor Conference
February 08, 2012 17:24 ET
|
Immune Pharmaceuticals Inc
EpiCept to Present at the 14th Annual BIO CEO & Investor Conference
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm...
EpiCept Files for AmiKet™ Fast Track Designation
February 07, 2012 00:01 ET
|
Immune Pharmaceuticals Inc
EpiCept Files for AmiKet™ Fast Track Designation
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX:...
EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include Evaluation of Potential Sale Transactions
January 24, 2012 14:05 ET
|
Immune Pharmaceuticals Inc
EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include
Evaluation of Potential Sale Transactions
TARRYTOWN, N.Y.--(BUSINESS...
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet™ Phase III CIPN Program and Regulatory Strategy
January 23, 2012 00:02 ET
|
Immune Pharmaceuticals Inc
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet™ Phase III CIPN
Program and Regulatory Strategy
Clear Pathway for NDA Filing Identified; Fast Track Application Encouraged
TARRYTOWN,...
EpiCept Corporation Reduces Exercise Price and Extends Expiration Date of June 2010 Series B Warrants
January 09, 2012 17:03 ET
|
Immune Pharmaceuticals Inc
EpiCept Corporation Reduces Exercise Price and Extends Expiration Date of June
2010 Series B Warrants
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept...
EpiCept Corporation Engages SunTrust Robinson Humphrey to Advise on Strategy to Maximize AmiKet™ Potential
January 09, 2012 00:02 ET
|
Immune Pharmaceuticals Inc
EpiCept Corporation Engages SunTrust Robinson Humphrey to Advise on Strategy to
Maximize AmiKet™ Potential
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))--...
EpiCept to Present at Two Upcoming Industry Conferences
January 05, 2012 17:02 ET
|
Immune Pharmaceuticals Inc
EpiCept to Present at Two Upcoming Industry Conferences
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and...
EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman of the Board
January 05, 2012 00:03 ET
|
Immune Pharmaceuticals Inc
EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman of the
Board
TARRYTOWN, N.Y. (January 5, 2012) – EpiCept Corporation (Nasdaq OMX Stockholm
Exchange and OTCQX: EPCT) today...
EpiCept Corporation Receives FDA Permission to Initiate AmiKet™ Phase III Clinical Development
December 23, 2011 00:02 ET
|
Immune Pharmaceuticals Inc
EpiCept Corporation Receives FDA Permission to Initiate AmiKet™ Phase III
Clinical Development
TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory
News:
EpiCept...